Shanghai Securities News, China Securities Network – Chongqing Pharmaceutical Holdings announced on the evening of December 10 that its investee subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd. (referred to as "Yaoyou Pharmaceutical"), together with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., signed a Collaboration and License Agreement (referred to as the "License Agreement") with Pfizer on December 9. Under the agreement, Yaoyou Pharmaceutical grants Pfizer exclusive rights for the development, use, production, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists (including YP05002) and products containing this active ingredient within the licensed territory (i.e., globally) and field (covering treatment, diagnosis, and prevention for all human and animal indications). For this license, Yaoyou Pharmaceutical is entitled to receive a non-refundable upfront payment of $150 million and up to $350 million in development milestone payments based on the clinical and commercial progress of the licensed product.

It is reported that YP05002 is an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist independently developed and owned by Yaoyou Pharmaceutical with proprietary intellectual property rights. It primarily activates human GLP-1R to promote insulin secretion and reduce glucagon secretion from the pancreas, inhibit gastric emptying and intestinal motility in the gastrointestinal tract, and suppress appetite to reduce energy intake through central mechanisms. It is intended for the treatment of type 2 diabetes, obesity, and related conditions. YP05002 is targeted for treating metabolic diseases, with potential indications including but not limited to long-term weight management, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (formerly known as non-alcoholic steatohepatitis, NASH).

As of December 9, YP05002 is in Phase I clinical trials in Australia. Chongqing Pharmaceutical Holdings' controlling subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd., holds a 38.67% equity stake in Yaoyou Pharmaceutical.

Background information shows that Pfizer is a globally leading biopharmaceutical company, founded in June 1942 and registered in Delaware, USA. It is listed on the New York Stock Exchange (stock symbol: "PFE") and focuses on discovering, developing, manufacturing, and selling high-quality innovative medicines and vaccines. According to its published financial reports, as of December 31, 2024, its total assets amounted to $213.4 billion, with net assets of $88.5 billion. In 2024, it achieved revenue of $63.6 billion and net income of $8.1 billion.

Chongqing Pharmaceutical Holdings stated that this licensing agreement reflects the partners' recognition of Yaoyou Pharmaceutical's innovative R&D capabilities. Through this license, the clinical development and commercialization of the licensed product are expected to accelerate globally, potentially benefiting more patients worldwide.

Reference：https://finance.eastmoney.com/a/202512103587950175.html